Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
about
Maternal immunizationGroup B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countriesMaternal group B Streptococcus-related stillbirth: a systematic reviewChallenges in reducing group B Streptococcus disease in African settings.Capsular Typing Method for Streptococcus agalactiae Using Whole-Genome Sequence DataAssociation between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort.DNA microarray-based typing of Streptococcus agalactiae isolates.Population structure and antimicrobial resistance of invasive serotype IV group B Streptococcus, Toronto, Ontario, CanadaBurden of invasive group B Streptococcus disease and early neurological sequelae in South African infants.Invasive Group B Streptococcal Disease in South Africa: Importance of Surveillance Methodology.Immunization in Canada: Update for 2015.Embedding surveillance into clinical care to detect serious adverse events in pregnancyImproving rates of maternal immunization: Challenges and opportunitiesKnowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trialCharacterization of invasive group B streptococcus strains from the greater Toronto area, Canada.Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products.Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants.Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination.Group B streptococcal immunisation of pregnant women for the prevention of early and late onset Group B streptococcal infection of the neonate as well as adult disease.Prevention of early onset group B streptococcal disease by universal antenatal culture-based screening in all public hospitals in Hong Kong.Screening for early-onset invasive group B Streptococcal disease in neonates in an Irish hospital (2001-2014): a retrospective audit.Group B Streptococci serotype distribution in pregnant women in Ghana: assessment of potential coverage through future vaccines.Colonization prevalence and antibiotic susceptibility of Group B Streptococcus in pregnant women over a 6-year period in Dongguan, China.Neonatal group B streptococcus disease in developing countries: are we ready to deploy a vaccine?Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants.Codevelopment of Microbiota and Innate Immunity and the Risk for Group B Streptococcal Disease.Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses.Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.From empiricism to rational design: a personal perspective of the evolution of vaccine development.Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology.Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches.Potential targets for next generation anti-microbial glycoconjugate vaccines.Obesity, Diabetes, and the Risk of Invasive Group B Streptococcal Disease in Nonpregnant Adults in the United States.Respiratory distress in the newbornPatterns of ischemic injury on brain images in neonatal group B Streptococcal meningitis
P2860
Q26853746-45E3E0AD-97AC-4BD7-AF04-E0D4E2E51713Q28075884-47702157-203D-455E-858D-34D298E5B242Q28082060-63A16D1C-6A54-4793-88FA-E9E7A3F2F29BQ30241490-1FF892CE-9C6A-48E8-80AB-5A34DDD4F601Q31056403-AE41AA90-1E9D-4FF6-ADF4-5541407DC627Q33689195-A284FF7D-DB96-44CC-A7C7-D3EA214E3AF3Q35036001-3F3283E8-A13A-48DF-B0C5-1B6948177A6DQ35229670-A37A6351-08AD-44F6-9988-A63705E21730Q35306303-9748C76E-1F8E-433C-B6BC-23930B04F05EQ35982773-DA1F6A29-0051-4349-9765-8668FE991C17Q36728581-D06F3F00-DBDB-415B-9A92-C5000339CF5BQ36755182-637B69D6-8EFC-4B22-886A-066528706433Q37130751-0C2E92A5-1FE4-4CDE-999F-5E0CD515B997Q37130808-38CBD9D6-6C3C-487D-8FA5-645F9C4691D0Q37713818-2B434162-D915-4C33-A50B-28FB1020354CQ37740442-1400A4C3-1C71-40C3-A2D8-9E870C72914CQ38253017-C6EF22FB-615B-4A28-9D0C-2B1AF6C6EA90Q38570903-4CC83089-481B-4C51-8FC6-E7B5A4526C16Q38844623-4D1A1531-978F-4F6B-BA04-9072BE06D219Q38893046-AB88BAEC-9980-4F92-8FBF-A99A12696BC4Q38918659-961B0992-729C-45FD-AFB4-F42F023A6808Q38973082-112C16FF-55CD-4AC5-9877-00848449B10FQ40091480-7826E69A-F34C-41D2-8D99-3CDC7CA1EF55Q40625732-A49ED46A-14EE-451B-B3FC-EF9654AE8D13Q41002917-23AFD4FE-7EC4-4418-BAFD-70A09D8E3ED7Q46247272-BBCD2C2C-3EEA-4CD1-8817-B0993D5E0337Q46301633-06FCF0ED-6691-4A59-A412-999D60C42A1FQ46954965-B98613A1-DB48-40F6-91D9-C8EBC736C3A9Q47633699-AF0F2196-226E-4DD2-B60D-8F25CDD530B6Q52624533-F5089361-3EAE-42B2-9A25-B5AA6FE159B8Q52665560-6F007EAD-5D71-45DC-85D1-6B64EA9AE7F1Q53701548-37AC103E-9339-40A7-AE64-DB476DAAD51AQ55415799-065E0D51-8BAA-4E29-ADAD-12BCF08C835AQ56474835-05EB0712-1BA3-4493-8C27-D37C86BA62BFQ58777111-3C80C774-323D-4F65-9694-3BE78D807312
P2860
Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Considerations for a phase-III ...... sive disease in young-infants.
@en
type
label
Considerations for a phase-III ...... sive disease in young-infants.
@en
prefLabel
Considerations for a phase-III ...... sive disease in young-infants.
@en
P2093
P921
P1433
P1476
Considerations for a phase-III ...... sive disease in young-infants.
@en
P2093
Ajoke Sobanjo-Ter Meulen
Alaine Izu
Paul T Heath
Peter M Dull
Stephanie Schrag
Ziyaad Dangor
P356
10.1016/J.VACCINE.2013.02.029
P407
P478
31 Suppl 4
P577
2013-08-01T00:00:00Z